title: It is time to ask what adenosine can do for cardioprotection.
abstract: Prevention and attenuation of ischemia and reperfusion injury in patients with acute coronary syndrome are critically important for cardiologists. To save these patients from deleterious ischemic insults, there are three different strategies. The first strategy is to increase ischemic tolerance before the onset of myocardial ischemia; the second is to attenuate the ischemia and reperfusion injury when an irreversible process of myocardial cellular injury occurs; the third is to treat the ischemic chronic heart failure that is caused by acute myocardial infarction. Adenosine, which is known to be cardioprotective against ischemia and reperfusion injury, may merit being used for these three cardioprotection strategies. First of all, adenosine induces collateral circulation via induction of growth factors, and triggers ischemic preconditioning, both of which induce ischemic tolerance in advance. Secondly, endogenous adenosine may mediate the infarct size-limiting effect of ischemic preconditioning, and exogenous adenosine is known to attenuate ischemia and reperfusion injury. Thirdly, we also revealed that adenosine metabolism is changed in patients with chronic heart failure, and increases in adenosine levels may attenuate the severity of ischemic heart failure. Therefore, adenosine therapy may improve the pathophysiology of ischemic chronic heart failure. Taking these factors together, we hereby propose potential tools for cardioprotection attributable to adenosine in ischemic hearts, and we postulate the use of adenosine therapy before, during, and after the onset of acute myocardial infarction.
authors.affiliation: Department of Internal Medicine and Therapeutics, Osaka University School of Medicine, Suita, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kitakaze
authors.forename: M
authors.initials: M
authors.lastname: Hori
mesh_terms: D015720:5'-Nucleotidase / Q000378:metabolism; D000241:Adenosine / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003097:Collateral Circulation; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D011493:Protein Kinase C / Q000378:metabolism
chemical_list: D002317:Cardiovascular Agents; D011493:Protein Kinase C; D015720:5'-Nucleotidase; D000241:Adenosine